HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Up 59.8% in January

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 21,438 shares, a growth of 59.8% from the December 31st total of 13,416 shares. Currently, 1.1% of the shares of the company are short sold. Based on an average daily volume of 42,653 shares, the short-interest ratio is presently 0.5 days. Based on an average daily volume of 42,653 shares, the short-interest ratio is presently 0.5 days. Currently, 1.1% of the shares of the company are short sold.

HCW Biologics Trading Down 2.6%

NASDAQ HCWB traded down $0.03 during trading on Friday, hitting $1.11. 80,407 shares of the company’s stock were exchanged, compared to its average volume of 64,519. The company has a market cap of $3.64 million, a PE ratio of -0.09 and a beta of 0.71. HCW Biologics has a fifty-two week low of $0.95 and a fifty-two week high of $41.20. The stock’s 50 day moving average price is $1.52 and its two-hundred day moving average price is $3.17.

HCW Biologics (NASDAQ:HCWB) last announced its quarterly earnings results on Friday, November 14th. The company reported ($2.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.58 by ($3.60). The company had revenue of $0.00 million for the quarter, compared to the consensus estimate of $7.00 million.

Institutional Investors Weigh In On HCW Biologics

A hedge fund recently bought a new stake in HCW Biologics stock. Golden State Wealth Management LLC bought a new position in HCW Biologics Inc. (NASDAQ:HCWB) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $40,000. Golden State Wealth Management LLC owned approximately 0.69% of HCW Biologics as of its most recent SEC filing. Institutional investors and hedge funds own 2.96% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, HCW Biologics presently has an average rating of “Hold” and an average target price of $35.00.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.